HighVista Strategies LLC Acquires 167,983 Shares of Evolus, Inc. $EOLS

HighVista Strategies LLC raised its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 289.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 226,025 shares of the company’s stock after buying an additional 167,983 shares during the quarter. HighVista Strategies LLC’s holdings in Evolus were worth $1,388,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. Manchester Capital Management LLC purchased a new position in Evolus during the second quarter valued at $26,000. State of Alaska Department of Revenue bought a new position in shares of Evolus during the 3rd quarter valued at about $26,000. Tower Research Capital LLC TRC boosted its holdings in shares of Evolus by 340.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock valued at $68,000 after purchasing an additional 5,691 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in shares of Evolus during the third quarter valued at about $48,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Evolus during the third quarter valued at about $62,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. BTIG Research reiterated a “buy” rating and issued a $13.00 target price on shares of Evolus in a research report on Wednesday, March 4th. HC Wainwright reduced their price objective on Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Mizuho set a $15.00 price objective on Evolus in a report on Wednesday, February 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Finally, Wall Street Zen lowered shares of Evolus from a “buy” rating to a “hold” rating in a report on Sunday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Insiders Place Their Bets

In other news, insider David Moatazedi sold 10,539 shares of the stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the sale, the insider owned 354,388 shares of the company’s stock, valued at approximately $2,533,874.20. This represents a 2.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.10% of the stock is owned by company insiders.

Evolus Price Performance

NASDAQ:EOLS opened at $5.01 on Monday. The firm has a market capitalization of $325.95 million, a price-to-earnings ratio of -6.19 and a beta of 1.02. The business has a 50 day simple moving average of $4.89 and a 200-day simple moving average of $6.13. Evolus, Inc. has a 1 year low of $4.09 and a 1 year high of $13.66.

Evolus (NASDAQ:EOLS) last released its earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.09). The firm had revenue of $90.30 million during the quarter, compared to analysts’ expectations of $89.58 million. As a group, analysts expect that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.